Michael Möller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael Möller has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Robert Gurny
Apidel SA , Geneva 1201 , Switzerland
7 shared publications- Robert Gurny
School of Pharmaceutical Sciences, University of Geneva, Geneva 1211, Switzerland
7 shared publications Karine Mondon
4 shared publications- Benjamin Nottelet
Department of Polymers for Health and Biomaterials, IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France; Department of Pharmacy, Nîmes University Hospital, 30900 Nimes, France
3 shared publications - Leonardo Scapozza
Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
3 shared publications - Robert Gurny
School of Pharmacy, University of Geneva, Geneva, Switzerland
3 shared publications
Latest Publications
- 18 June 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (7) , 2539-2547
Cyclosporine A-Loaded Nanocarriers for Topical Treatment of Murine Experimental Autoimmune Uveoretinitis
In the present study, tissue distribution and the therapeutic effect of topically applied cyclosporine A (CsA)-loaded methoxy-poly(ethylene-glycol)-hexyl substituted poly(lactic acid) (mPEGhexPLA) nanocarriers (ApidSOL) on experimental autoimmune uveitis (EAU) were investigated. The CsA-loaded mPEGhexPLA nanocarrier was tolerated well locally and showed no signs of immediate toxicity after repeated topical application in mice with EAU. Upon unilateral CsA treatment, CsA accumulated predominantly in the corneal and sclera-choroidal tissue of the treated eye and in lymph nodes (LN). This regimen reduced EAU severity in treated eyes compared to PBS-treated controls. This improvement was accompanied by reduced T-cell count, T-cell proliferation, and IL-2 secretion of cells from ipsilateral LN. In conclusion, topical treatment with CsA-loaded mPEGhexPLA nanocarriers significantly improves the outcome of EAU.
- 18 June 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (7) , 2539-2547
Cyclosporine A-Loaded Nanocarriers for Topical Treatment of Murine Experimental Autoimmune Uveoretinitis
In the present study, tissue distribution and the therapeutic effect of topically applied cyclosporine A (CsA)-loaded methoxy-poly(ethylene-glycol)-hexyl substituted poly(lactic acid) (mPEGhexPLA) nanocarriers (ApidSOL) on experimental autoimmune uveitis (EAU) were investigated. The CsA-loaded mPEGhexPLA nanocarrier was tolerated well locally and showed no signs of immediate toxicity after repeated topical application in mice with EAU. Upon unilateral CsA treatment, CsA accumulated predominantly in the corneal and sclera-choroidal tissue of the treated eye and in lymph nodes (LN). This regimen reduced EAU severity in treated eyes compared to PBS-treated controls. This improvement was accompanied by reduced T-cell count, T-cell proliferation, and IL-2 secretion of cells from ipsilateral LN. In conclusion, topical treatment with CsA-loaded mPEGhexPLA nanocarriers significantly improves the outcome of EAU.
- 1 November 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 242, 16-24
Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis
- 1 November 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 242, 16-24
Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis
- Open Access
- 20 February 2016
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 4 (1) , 11
Histologic Assessment of Drug-Eluting Grafts Related to Implantation Site
Drug-eluting vascular prostheses represent a new direction in vascular surgery to reduce early thrombosis and late intimal hyperplasia for small calibre grafts. Subcutaneous implantation in rats is a rapid and cost-effective screening model to assess the drug-elution effect and could, to some extent, be useful to forecast results for vascular prostheses. We compared biological and histological responses to scaffolds in different implantation sites. Polycaprolactone (PCL), paclitaxel-loaded PCL (PCL-PTX) and dexamethasone-loaded PCL (PCL-DXM) electrospun scaffolds were implanted subcutaneously and in an infrarenal abdominal aortic model in rats for up to 12 weeks. At the conclusion of the study, a histological analysis was performed. Cellular graft invasion revealed differences in the progression of cellular infiltration between PCL-PTX and PCL/PCL-DXM groups in both models. Cell infiltration increased over time in the aortic model compared to the subcutaneous model for all groups. Cell counting revealed major differences in fibroblast, macrophage and giant cell graft colonisation in all groups and models over time. Macrophages and giant cells increased in the PCL aortic model; whereas in the subcutaneous model these cell types increased only after three weeks or even decreased in the drug-eluting PCL groups. Other major findings were observed only in the aortic replacement such as extracellular matrix deposition and neo-angiogenesis. The subcutaneous implant model can be used for screening, especially when drug-eluting effects are studied. However, major histological differences were observed in cell type reaction and depth of cell penetration compared to the aortic model. Our results demonstrate that the implantation site is a critical determinant of the biological response.
- 20 February 2016
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 4 (1) , 11
Open AccessHistologic Assessment of Drug-Eluting Grafts Related to Implantation Site
Drug-eluting vascular prostheses represent a new direction in vascular surgery to reduce early thrombosis and late intimal hyperplasia for small calibre grafts. Subcutaneous implantation in rats is a rapid and cost-effective screening model to assess the drug-elution effect and could, to some extent, be useful to forecast results for vascular prostheses. We compared biological and histological responses to scaffolds in different implantation sites. Polycaprolactone (PCL), paclitaxel-loaded PCL (PCL-PTX) and dexamethasone-loaded PCL (PCL-DXM) electrospun scaffolds were implanted subcutaneously and in an infrarenal abdominal aortic model in rats for up to 12 weeks. At the conclusion of the study, a histological analysis was performed. Cellular graft invasion revealed differences in the progression of cellular infiltration between PCL-PTX and PCL/PCL-DXM groups in both models. Cell infiltration increased over time in the aortic model compared to the subcutaneous model for all groups. Cell counting revealed major differences in fibroblast, macrophage and giant cell graft colonisation in all groups and models over time. Macrophages and giant cells increased in the PCL aortic model; whereas in the subcutaneous model these cell types increased only after three weeks or even decreased in the drug-eluting PCL groups. Other major findings were observed only in the aortic replacement such as extracellular matrix deposition and neo-angiogenesis. The subcutaneous implant model can be used for screening, especially when drug-eluting effects are studied. However, major histological differences were observed in cell type reaction and depth of cell penetration compared to the aortic model. Our results demonstrate that the implantation site is a critical determinant of the biological response.
- 1 January 2016
- Published by Springer Nature
- p. 223-240
Polymeric Micelles in Dermal and Transdermal Delivery
- 1 January 2016
- Published by Springer Nature
- p. 223-240
Polymeric Micelles in Dermal and Transdermal Delivery
- 1 September 2015
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 95, 250-260
Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment
- 1 September 2015
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 95, 250-260
Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment
- 1 February 2015
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 90, 70-79
A novel oxido-viscosifying Hyaluronic Acid-antioxidant conjugate for osteoarthritis therapy: Biocompatibility assessments
- 1 February 2015
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 90, 70-79
A novel oxido-viscosifying Hyaluronic Acid-antioxidant conjugate for osteoarthritis therapy: Biocompatibility assessments
- Open Access
- 1 February 2013
- Published by Swiss Chemical Society in Chimia
- Vol. 67 (1-2)
Validation of a Novel Molecular Dynamics Simulation Approach for Lipophilic Drug Incorporation into Polymer Micelles
- 1 February 2013
- Published by Swiss Chemical Society in Chimia
- Vol. 67 (1-2)
Open AccessValidation of a Novel Molecular Dynamics Simulation Approach for Lipophilic Drug Incorporation into Polymer Micelles
- 3 December 2012
- Published by Elsevier in Journal of Controlled Release
- Vol. 165 (3) , 199-206
In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer
- 3 December 2012
- Published by Elsevier in Journal of Controlled Release
- Vol. 165 (3) , 199-206
In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer